secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K
Filed at:   2021-07-26T23:59:59+00:00
Accession:  0001157523-21-000916
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend
----------------------------------------------------------------------------

- Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.
- Raises full-year revenue and earnings guidance; initiates Q3 guidance.
- Agrees to acquire BioLegend, a leading antibody & research reagent provider.
- GAAP operating margin 27.1% (vs 21.6% Q2 2020); adjusted margin 33.5% (vs 28.1%).
- Earnings call moved to July 26 at 8:00 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/0001157523-21-000916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/a52464567.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-000916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer